Author + information
- Received October 26, 2007
- Revision received May 7, 2008
- Accepted May 13, 2008
- Published online September 23, 2008.
- Sripal Bangalore, MD, MHA,
- David Wild, MD,
- Sanobar Parkar, MD, MPH,
- Marrick Kukin, MD, FACC and
- Franz H. Messerli, MD, FACC⁎ ()
- ↵⁎Reprint requests and correspondence:
Dr. Franz H. Messerli, Division of Cardiology, St. Luke's-Roosevelt Hospital, Columbia University College of Physicians and Surgeons, 1000 10th Avenue, Suite 3B-30, New York, New York 10019
Objectives This study sought to evaluate the efficacy of beta-blockers (BBs) for primary prevention of heart failure (HF) in patients with hypertension.
Background The American College of Cardiology/American Heart Association staging for HF classifies patients with hypertension as stage A HF, for which BBs are a treatment option. However, the evidence to support this is unknown.
Methods We conducted a MEDLINE/EMBASE/CENTRAL search of randomized controlled trials that evaluated BB as first-line therapy for hypertension with follow-up for at least 1 year and with data on new-onset HF. The primary outcome was new-onset HF. Secondary outcomes were all-cause mortality, cardiovascular mortality, myocardial infarction, and stroke.
Results Among the 12 randomized controlled trials, which evaluated 112,177 patients with hypertension, BBs reduced blood pressure by 12.6/6.1 mm Hg when compared with placebo, resulting in a 23% (trend) reduction in HF risk (p = 0.055). When compared with other agents, the antihypertensive efficacy of BBs was comparable, which resulted in similar but no incremental benefit for HF risk reduction in the overall cohort (risk ratio: 1.00; 95% confidence interval: 0.92 to 1.08), in the elderly (≥60 years) or in the young (<60 years). Analyses of secondary outcomes showed that BBs confirmed similar but no incremental benefit for the outcomes of all-cause mortality, cardiovascular mortality, and myocardial infarction but increased stroke risk by 19% in the elderly.
Conclusions In hypertensive patients, primary prevention of HF is strongly dependent on blood pressure reduction. When compared with other antihypertensive agents, there was similar but no incremental benefit of BBs for the prevention of HF. However, given the increased risk of stroke in the elderly, BBs should not be considered as first-line agents for prevention of HF.
Dr. Kukin is on the Speakers' Bureau of AstraZeneca and Novartis, and has received research grants from Medtronic, Amgen, and Impulse Dynamics. Dr. Messerli is on the Speakers' Bureau of GlaxoSmithKline, Novartis, Pfizer, AstraZeneca, Bayer, Boehringer Ingelheim, Forest, Merck, Sankyo, and Sanofi, and has received research grants from GlaxoSmithKline, Pfizer, Novartis, and CardioVascular Therapeutics.
- Received October 26, 2007.
- Revision received May 7, 2008.
- Accepted May 13, 2008.
- American College of Cardiology Foundation